Work

Fixed-duration subcutaneous (SC) mosunetuzumab (Mosun) in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Interim analysis and patient-reported outcomes (PROs) from the phase 2 MorningSun study.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.7029

Authors: Ian W. Flinn, John M. Burke, Aung M. Tun, Ayed Ayed, Juliana M. L. Biondo, Mei Wu, Farah Hossain, Yong Mun, Rona Farighi, Avrita Singh, Jamal Misleh, Shachar Peles, L. Elizabeth Budde, Jose C. Villasboas, Jeff P. Sharman

Institutions: Tennessee Oncology, Rocky Mountain Cancer Centers, The University of Kansas Cancer Center, Genentech, National Cancer Institute, Florida Cancer Specialists & Research Institute, City Of Hope National Medical Center, Mayo Clinic, Willamette Valley Cancer Institute and Research Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Genentech

OpenAlex ID: W7162539602

Cites:

Cited by: 1

Related to: